Mediclinic International plc
ANHGY
Other OTC5.49
USD
- -
- -
Mediclinic International plc
ANHGY
(Other OTC)
Recent
price
5.49
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mediclinic International plc (MDC: JSE; ANHGY: OTC) operates as a private healthcare provider, delivering acute care hospital services and comprehensive medical facilities across multiple regions. The company owns and manages a network of hospitals offering a wide range of services, including general acute care; specialist treatments in cardiology, oncology, neurology, orthopedics, and maternity; diagnostic imaging and pathology laboratories; outpatient clinics and day surgery centers; and ancillary services such as pharmacies and rehabilitation facilities. Its primary brands include Mediclinic Southern Africa, Mediclinic Middle East, and Hirslanden in Switzerland, serving patients through high-acuity hospitals equipped with advanced medical technology and multidisciplinary teams. Founded in 2012 and headquartered in Stellenbosch, South Africa, Mediclinic International plc primarily targets private healthcare markets in Southern Africa, the United Arab Emirates, and Switzerland, with operations spanning over 70 hospitals and more than 20,000 beds. The company caters to insured patients, self-pay individuals, and corporate clients seeking premium medical care in competitive markets characterized by rising demand for quality private hospitals. It maintains strategic subsidiaries under its regional brands and focuses on expanding capacity in high-growth areas like the UAE and Switzerland. In recent developments, Mediclinic International has pursued operational enhancements and strategic expansions, including the integration of digital health initiatives and capacity upgrades at key facilities in the Middle East and Switzerland within the last two years. The company completed refinancing efforts to strengthen its balance sheet and announced plans for new hospital developments in the UAE to meet growing demand. No major acquisitions or name changes have been reported recently, with focus remaining on organic growth and cost efficiencies amid regional healthcare sector recovery.